Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12534240 | 1.00 | SPHK1 (0.34) | SPHK1USP2SMN1; SMN2HCRTR2CHRM2 | |
| SCHEMBL25251925 | 1.00 | SPHK1 (0.34) | SPHK1USP2SMN1; SMN2HCRTR2CHRM2 | |
| SCHEMBL15311113 | 1.00 | SPHK1 (0.34) | SPHK1USP2SMN1; SMN2HCRTR2CHRM2 | |
| SCHEMBL17212829 | 1.00 | SPHK1 (0.34) | SPHK1USP2SMN1; SMN2HCRTR2CHRM2 | |
| SCHEMBL12713986 | 0.87 | SPHK1 (0.34) | SPHK1USP2SMN1; SMN2HCRTR2BRD4 | |
| SCHEMBL28460541 | 0.87 | SPHK1 (0.34) | SPHK1USP2SMN1; SMN2HCRTR2BRD4 | |
| SCHEMBL25054628 | 0.83 | SPHK1 (0.34) | SPHK1BRD4 | |
| SCHEMBL25054605 | 0.83 | SPHK1 (0.34) | SPHK1BRD4 | |
| SCHEMBL1614640 | 0.81 | SPHK1 (0.31) | SPHK1HCRTR2 | |
| SCHEMBL1614637 | 0.81 | SPHK1 (0.31) | SPHK1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024220546-A2 | ANTIBODIES AND ANTIBODY-DRUG CONJUGATES AND METHODS OF USE AND SYNTHETIC PROCESSES AND INTERMEDIATES | PEAK BIO, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| US-11691982-B2 | Thailanstatin analogs | PH PHARMA CO., LTD. (KR) | 2023-07-04 | — | — | US | disclosed |
| US-11691982-B2 | Thailanstatin analogs | PH PHARMA CO., LTD. (KR) | 2023-07-04 | — | — | US | disclosed |
| US-11691982-B2 | Thailanstatin analogs | PH PHARMA CO., LTD. (KR) | 2023-07-04 | — | — | US | disclosed |
| US-11584754-B2 | Derivatives of thailanstatin A, methods of treatment and methods of synthesis thereof | WILLIAM MARSH RICE UNIVERSITY (US) | 2023-02-21 | — | — | US | disclosed |
| US-9771377-B2 | Synthesis of FR901464 and analogs with antitumor activity | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2017-09-26 | — | — | US | disclosed |
| US-20150307512-A1 | SYNTHESIS OF FR901464 AND ANALOGS WITH ANTITUMOR ACTIVITY | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2015-10-29 | — | — | US | disclosed |
| WO-2014100367-A1 | SYNTHESIS OF FR901464 AND ANALOGS WITH ANTITUMOR ACTIVITY | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2014-06-26 | — | — | WO | disclosed |
| EP-1157019-B1 | 4-ALKENYL (AND ALKYNYL) OXINDOLES AS INHIBITORS OF CYCLIN-DEPENDENT KINASES, IN PARTICULAR CDK2 | HOFFMANN LA ROCHE (CH) | 2003-03-19 | — | — | EP | disclosed |
| EP-1157019-A1 | 4-ALKENYL (AND ALKYNYL) OXINDOLES AS INHIBITORS OF CYCLIN-DEPENDENT KINASES, IN PARTICULAR CDK2 | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-28 | — | — | EP | disclosed |
| US-6303793-B1 | INTERMEDIATES FOR CYCLIN-DEPENDENT KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. | 2001-10-16 | — | — | US | disclosed |
| US-6252086-B1 | CYCLIN-DEPENDENT KINASES INHIBITORS; ANTICANCER AGENTS | HOFFMANN-LA ROCHE INC. | 2001-06-26 | — | — | US | disclosed |
| US-6130239-A | INHIBIT CYCLIN-DEPENDENT KINASES | HOFFMANN-LA ROCHE INC. (US) | 2000-10-10 | — | — | US | disclosed |
| WO-2000035908-A1 | 4-ALKENYL (AND ALKYNYL) OXINDOLES AS INHIBITORS OF CYCLIN-DEPENDENT KINASES, IN PARTICULAR CDK2 | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691982-B2 | Thailanstatin analogs | CD47, SUGT1, TPT1 | SPHK1 3282/4885USP2 4768/4885SMN1; SMN2 2250/4885 |
| US-11584754-B2 | Derivatives of thailanstatin A, methods of treatment and methods of synthesis thereof | NAMPT, FNTA, GNPAT | SPHK1 1299/4885USP2 4706/4885SMN1; SMN2 2181/4885 |
| US-20150307512-A1 | SYNTHESIS OF FR901464 AND ANALOGS WITH ANTITUMOR ACTIVITY | RBM17, SF3B1, RTCB | SPHK1 1268/4885USP2 3739/4885SMN1; SMN2 425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.